Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Inositol-stabilized arginine silicate** (ASI) is a complex produced by combining arginine, a silicate salt such as potassium silicate, and inositol. This combination solubilizes the silicate, resulting in high bioavailability for both arginine and silicon. ASI dissociates in the stomach, releasing arginine, silicate, and inositol. It is primarily developed as a dietary and sports supplement for enhancing **circulating arginine and nitric oxide (NO)**, which can increase vasodilation, blood flow, and nutrient delivery. Studies show benefits for **cognitive function**, exercise recovery, muscle damage reduction, and support for cardiovascular health and bone formation. Its main mechanisms relate to improved arginine and silicon bioavailability, leading to elevated NO production and upregulation of physiological processes such as vasodilation and improved cognitive outcomes[1][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inositol-stabilized arginine silicate.